Do you want to read an article? Please log in or register.
Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis
Multiple Sclerosis
Related content
Multiple Sclerosis
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis
JAMA.
Brown JWL, Coles A, Horakova D, Havrdova E, Izquierdo G, Prat A, Girard M, Duquette P, Trojano M, Lugaresi A, Bergamaschi R, Grammond P, Alroughani R, Hupperts R, McCombe P, Van Pesch V, Sola P, Ferraro D, Grand'Maison F, Terzi M, Lechner-Scott J, Flechter S, Slee M, Shaygannejad V, Pucci E, Granella F, Jokubaitis V, Willis M, Rice C, Scolding N, Wilkins A, Pearson OR, Ziemssen T, Hutchinson M, Harding K, Jones J, McGuigan C, Butzkueven H, Kalincik T, Robertson N, MSBase Study Group
doi: 10.1001/jama.
Multiple Sclerosis
Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis
JAMA Neurol.
Hughes J, Jokubaitis V, Lugaresi A, Hupperts R, Izquierdo G, Prat A, Girard M, Duquette P, Grand'Maison F, Grammond P, Sola P, Ferraro D, Ramo-Tello C, Trojano M, Slee M, Shaygannejad V, Boz C, Lechner-Scott J, Van Pesch V, Pucci E, Solaro C, Verheul F, Terzi M, Granella F, Spitaleri D, Alroughani R, Jun JK, Fambiatos A, Van der Walt A, Butzkueven H, Kalincik T, MSBase Study Group
doi: 10.1001/jamaneurol.
Multiple Sclerosis
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension
Lancet Neurol.
Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdová EK, Jeffery D, Miller A, Sellebjerg F, Cadavid D, Mikol D, Steiner D
doi: 10.1016/S1474-4422
Multiple Sclerosis
Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies
Lancet Neurol.
Ho PR, Koendgen H, Campbell N, Haddock B, Richman S, Chang I
doi: 10.1016/
RECOMMENDED
Multiple Sclerosis
Disability progression in relapse-free multiple sclerosis patients on fingolimod versus interferon-beta/glatiramer acetate
★ 1
Recommended by
Prof. Dr Claudio Gobbi, Faculty Member
Mult Scler.
von Wyl V, Benkert P, Moser A, Lorscheider J, Décard B, Hänni P, Lienert C, Kuhle J, Derfuss T, Kappos L, Yaldizli Ö
doi: 10.1177/1352458520918489.
Multiple Sclerosis
Progressive multiple sclerosis: from pathogenic mechanisms to treatment
Brain.
Correale J, Gaitán MI, Ysrraelit MC, Fiol MP
doi: 10.1093/brain/aww258.
Multiple Sclerosis
Long-term disability progression in primary progressive multiple sclerosis: a 15-year study
Brain.
Rocca MA, Sormani MP, Rovaris M, Caputo D, Ghezzi A, Montanari E, Bertolotto A, Laroni A, Bergamaschi R, Martinelli V, Comi G, Filippi M
doi: 10.1093/brain/awx250.
Multiple Sclerosis
Anti-inflammatory disease modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study
Eur J Neurol.
Lorscheider J, Kuhle J, Izquierdo G, Lugaresi A, Havrdova E, Horakova D, Hupperts R, Duquette P, Girard M, Prat A, Grand'Maison F, Grammond P, Sola P, Ferraro D, Trojano M, Ramo-Tello C, Lechner-Scott J, Pucci E, Solaro C, Slee M, Van Pesch V, Menoyo JLS, van der Walt A, Butzkueven H, Kappos L, Kalincik T; MSBase Study Group
doi: 10.1111/ene.13824.
COMMENTED
Multiple Sclerosis
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
Lancet.
Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T, Wolf C, Wallström E, Dahlke F; EXPAND Clinical Investigators
doi: 10.1016/